Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
47
days
The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026
AuthorsSerena Pillozzi; Elisa Giommoni; Giulia Petroni; Daniele Rossini; Daniele Lavacchi; Marco Brugia; Andrea Galli; Lorenzo Antonuzzo
Affiliations1. Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy; 2. Pancreas Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; 3. Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; 4. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
72
days
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data
AuthorsMing-Yu Lai; Hao-Xiang Wu; Ming-Ming He; Wen-Long Guan; Sheng Xu; Han Hu; Ya-Ling Xu; Feng-Hua Wang; Rui-Hua Xu; Miao-Zhen Qiu
Affiliations1. Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China; 2. Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China; 3. Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China; 4. Global Statistics and Data Science, BeOne Medicines, Ltd., Shanghai, China; 5. Clinical Biomarker Sciences and CDx Development, BeOne Medicines, Ltd., Beijing, China; 6. Clinical Development, BeOne Medicines, Ltd., Shanghai, China
101
days
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment
AuthorsMonika Szczepanowski; Johanna Richter; Sonja Bendig; Lorenz Bastian; Miriam Kelm; Veronika Beck; Thomas Beder; Guranda Chitadze; Michaela Kotrová; Johannes Duell; Christoph Faul; Johannes Gärtner; Alina Hartmann; Britta Kehden; Eva Maria Murga Penas; Martin Neumann; Matthias Ritgen; Wiebke Schrader; Björn Steffen; Heiko Trautmann; Andreas Viardot; Thomas Burmeister; Claudia D. Baldus; Stefan Schwartz; Nicola Gökbuget; Monika Brüggemann
Affiliations1. Medicine Department II, Hematology and Oncology, University Medical Center Schleswig-Holstein (UKSH), Kiel, Germany; 2. University Cancer Center Schleswig-Holstein (UCCSH), Kiel, Germany; 3. Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 4. Clinical Research Unit ’CATCH ALL’ (KFO 5010), Kiel, Germany; 5. Department of Internal Medicine II, Würzburg University Hospital, University of Würzburg, Würzburg, Germany; 6. Internal Medicine II, University Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen, Tübingen, Germany; 7. Department of Medicine 5, Oncology, Hematology and Bone Marrow Transplantation Unit, Klinikum Nürnberg Nord, Nürnberg, Germany; 8. Institute of Human Genetics, University Medical Center Schleswig- Holstein (UKSH), Lübeck, Germany; 9. Medicine Department II, Johann Wolfgang Goethe University, Frankfurt, Germany; 10. Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany; 11. Department of Hematology, Oncology and Tumor Immunology, Campus Virchow Klinikum, Campus Virchow Klinikum, Charité - Universitätsmedizin, Berlin, Germany; 12. Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin , Berlin, Germany; 13. Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany; 14. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 15. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany
58
days
Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting
AuthorsYan-Ruide Li; Zhengyao Shao; Haochen Nan
Affiliations1. Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, USA; 2. Department of Bioengineering, University of California, Los Angeles, USA; 3. Goodman-Luskin Microbiome Center, University of California, Los Angeles, USA; 4. Department of Pharmacology, University of California San Diego, La Jolla, USA
66
days
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer
AuthorsChang Liu; Hongxi Zeng; Jiarui Li; Panpan Zhang; Dan Liu; Miao Zhang; Ran Xue; Jifang Gong; Xiaotian Zhang; Yu Sun; Lin Shen; Changsong Qi
Affiliations1. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China; 2. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; 3. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China; 4. State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China; 5. Beijing Key Laboratory of Cell & Gene Therapy for Solid Tumor, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China
71
days
Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density
AuthorsHaochen Nan; Xinyuan Shen; Youcheng Yang; Shubing Wang; Yan-Ruide Li
Affiliations1. Department of Bioengineering, University of California, Los Angeles, USA; 2. Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, USA; 3. Goodman-Luskin Microbiome Center, University of California, Los Angeles, USA
126
days
BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88 L265P -induced PIM1 stability
AuthorsYan Yuan; Bo Dai; Haoshu Zhong; Jiajun Zheng; Zhen Fan; Di Chen; Qian Wang; Hao Wu; Yuan Li; Ping Zhu; Tianling Ding; Shu Wang; Kunpeng Wu; Yu Zhang; Zhenhua Wang; Rui Feng; Fengping Zhu; Kang Zheng; Zhiyong Qin; Bojie Yang; Hong Chen; Xiaolei Lin; Yu Yao; Dongxiao Zhuang; Zhifeng Shi; Ying Mao; Tong Chen
Affiliations1. Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China; 2. Center of Precision Medicine for Blood Diseases, Fudan University, Shanghai, China; 3. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China; 4. Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China; 5. Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China; 6. Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China; 7. Institute of Medicine, Huashan Hospital, Fudan University, Shanghai, China; 8. School of Data Science, Fudan University, Shanghai, China
50
days
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting
AuthorsYagya Ahlawat; Heng Jiang; Delong Liu
Affiliations1. Division of Hematology and Oncology, Westchester Medical Center, New York Medical College, Valhalla, USA; 2. Department of Internal Medicine, Westchester Medical Center, New York Medical College, Valhalla, USA
75
days
Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting
AuthorsPritika Sharma; Heng Jiang; Delong Liu
Affiliations1. Division of Hematology and Oncology, Westchester Medical Center and New York Medical College, Valhalla, USA; 2. Department of Internal Medicine, Westchester Medical Center, Valhalla, USA
94
days
Circulating tumor DNA in breast cancer: updates from SABCS 2025
AuthorsIris Zhi; Xianghui Zou; Min Sun; Nancy Chan; Naomi Ko; Neil Vasan; Shridar Ganesan; Cynthia Ma
Affiliations1. Division of Hematology and Medical Oncology, NYU Langone Perlmutter Cancer Center, NYU Grossman Long Island School of Medicine, Mineola, USA; 2. Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, USA; 3. Division of Hematology and Medical Oncology, NYU Langone Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, USA; 4. Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days